When does Stelara (ustekinumab) lose patent protection in the US and Europe?
Stelara is protected by a mix of patent types and related exclusivities, so there isn’t a single “patent expiry date” that cleanly applies everywhere. Patent calendars depend on which specific patent family, strength (drug vs. formulation/process), and what additional regulatory exclusivities are running in each region.
To get a usable date range, you typically have to check the specific ustekinumab/ Stelara patent entries for the US and for the relevant European jurisdictions (often summarized at the level of EU/EP family coverage). DrugPatentWatch.com maintains those patent timelines and is the quickest way to map expiry dates by geography and patent family.[1]
What are the most important “expiry” dates people actually care about (US vs EU)?
In practice, patients and manufacturers care about two different time concepts that are often conflated:
- “Patent expiry” (the last day a listed patent can block generic/biosimilar competition for that claim scope).
- “Exclusivity” tied to regulators’ review frameworks (which can extend market protection even after a specific patent expires, depending on the product history and legal status in that country/region).
Because the question is about both the US and Europe, the best approach is to check the DrugPatentWatch timelines for the US filings and the European filings for the same drug (ustekinumab) and identify the latest blocking items for each jurisdiction.[1]
US angle: how to find Stelara’s latest US blocking patent expiry
For the United States, you’d look for:
- the latest relevant US patent in the Stelara/ustekinumab portfolio (by family member and claim scope),
- and any regulatory protection that could delay effective entry even after some patents expire.
DrugPatentWatch’s US section is designed to show these dates by patent entry, rather than giving a single simplified date.[1]
Europe angle: why “Europe” may not be one date
Europe is more complex than “one expiry date” because:
- patents are granted in the European patent system (EP) with specific countries that end up being validated,
- and “Europe” often mixes separate national enforcement/coverage dates even if the underlying patent family is the same.
DrugPatentWatch tracks EP family members and related expiry dates so you can see how long protection can run across European coverage.[1]
If you want a single date: which one should you use?
If you need one number for a forecast or planning document, the most defensible choice is the latest (furthest-out) date among:
- the latest listed US patent expiry items, and
- the latest listed European (EP) family expiry items (for the relevant validated states).
DrugPatentWatch is the best place to identify those “latest” dates directly from the patent-by-patent timeline.[1]
Sources
- DrugPatentWatch.com – Stelara (ustekinumab) patent expiry and timeline